IPIX - possible due diligence : Pfizer news out
Post# of 72446
(Total Views: 750)
Posted On: 10/28/2018 4:10:11 PM
IPIX - possible due diligence :
Pfizer news out : October 23, 2018
Pfizer teams up to create "Cerevel Therapeutics" a new neuroscience-focused company with Bain Capital a private equity investment firm.
Pfizer felt that placing this set of neuroscience assets, after its decision to curtail research within the area, in a company with dedicated focus and expertise in CNS was the optimal next step. Pfizer will retain a 25 percent equity position in Cerevel. Two senior Pfizer executives, Morris Birnbaum, MD, PhD, Senior Vice President, Chief Scientific Officer of Internal Medicine, and Doug Giordano, Senior Vice President of Worldwide Business Development will serve on the Cerevel Board of Directors, along with Adam Koppel and Chris Gordon, Managing Directors of Bain Capital. The company will be based in the Greater Boston area.
Now from IPIX 10k : 》
Other Compounds Owned by the Company
The Company owns other compounds which have been identified as possible candidates for development for treating diseases including autism (KM 391), arthritis (KM277), asthma (KM 278), MS/ALS/Parkinson’s (KM 362), cancer (KM 3174), hypertensive emergency (KM 732), and bacterial and fungal infections. Development of these compounds is on hold while the Company focuses its resources on its lead compounds
A possible Pfizer & It's newly formed Cereval Therapeutics , funny that it happens to be newly headquartered in a city above Boston MA. ???
Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.
Correlation here to more Pfizer rumor mill or rubbing the genie lamp to hard to intriguing IPIX possibilities of continued partnership talks and does Dr.Bertolino know anybody to the above mentioned executives when he was at Pfizer ??? ........all imho,tryz
Pfizer news out : October 23, 2018
Pfizer teams up to create "Cerevel Therapeutics" a new neuroscience-focused company with Bain Capital a private equity investment firm.
Pfizer felt that placing this set of neuroscience assets, after its decision to curtail research within the area, in a company with dedicated focus and expertise in CNS was the optimal next step. Pfizer will retain a 25 percent equity position in Cerevel. Two senior Pfizer executives, Morris Birnbaum, MD, PhD, Senior Vice President, Chief Scientific Officer of Internal Medicine, and Doug Giordano, Senior Vice President of Worldwide Business Development will serve on the Cerevel Board of Directors, along with Adam Koppel and Chris Gordon, Managing Directors of Bain Capital. The company will be based in the Greater Boston area.
Now from IPIX 10k : 》
Other Compounds Owned by the Company
The Company owns other compounds which have been identified as possible candidates for development for treating diseases including autism (KM 391), arthritis (KM277), asthma (KM 278), MS/ALS/Parkinson’s (KM 362), cancer (KM 3174), hypertensive emergency (KM 732), and bacterial and fungal infections. Development of these compounds is on hold while the Company focuses its resources on its lead compounds
A possible Pfizer & It's newly formed Cereval Therapeutics , funny that it happens to be newly headquartered in a city above Boston MA. ???
Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.
Correlation here to more Pfizer rumor mill or rubbing the genie lamp to hard to intriguing IPIX possibilities of continued partnership talks and does Dr.Bertolino know anybody to the above mentioned executives when he was at Pfizer ??? ........all imho,tryz
(6)
(0)